nach oben

International Urogynecology Journal

Erschienen in:

12.11.2019 | Editorial

Combination pharmacotherapy for the treatment of the overactive bladder syndrome: a new solution for an old problem?

verfasst von: Ahmed El-Zawahry, Diaa E. E. Rizk

Erschienen in: International Urogynecology Journal | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Excerpt

Overactive bladder syndrome (OAB) is a chronic urological condition that affects almost 20% of the population with a significant adverse impact on the quality of life. OAB may also have serious health consequences including mortality secondary to the increased risk of depression, falls and fractures. Thus far, the use of antimuscarinic therapy in OAB patients has been disappointing with reported compliance rates between 17%–35% after 2 years. Critical appraisal of novel pharmacological modalities for treatment of OAB, therefore, remains a research priority. …

Monteiro S, Riccetto C, Araujo A, Galo L, Brito N, Botelho S. Efficacy of pelvic floor muscle training in women with overactive bladder syndrome: a systematic review. Int Urogynecol J. 2018;29(11):1565–73. https://doi.org/10.1007/s00192-018-3602-x.CrossRefPubMed

Goldman HB, Oelke M, Kaplan SA, Kitta T, Russell D, Carlsson M, et al. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose? Int Urogynecol J. 2019;30(2):239–44. https://doi.org/10.1007/s00192-018-3640-4.CrossRefPubMed

Wang CC, Jiang YH, Kuo HC. Efficacy and adherence of flexibly adding on a second antimuscarinic agent for patients with refractory overactive bladder. Low Urin Tract Symptoms. 2017;9(1):27–32. https://doi.org/10.1111/luts.12103.CrossRefPubMed

Hsu FC, Weeks CE, Selph SS, Blazina I, Holmes RS, McDonagh MS. Updating the evidence on drugs to treat overactive bladder: a systematic review. Int Urogynecol J. 2019. https://doi.org/10.1007/s00192-019-04022-8.

Kelleher C, Hakimi Z, Zur R, Siddiqui E, Maman K, Aballea S, et al. Efficacy and tolerability of mirabegron compared with antimuscarinic monotherapy or combination therapies for overactive bladder: a systematic review and network meta-analysis. Eur Urol. 2018;74(3):324–33. https://doi.org/10.1016/j.eururo.2018.03.020.CrossRefPubMed

Staskin D, Herschorn S, Fialkov J, Tu LM, Walsh T, Schermer CR. A prospective, double-blind, randomized, two-period crossover, multicenter study to evaluate tolerability and patient preference between mirabegron and tolterodine in patients with overactive bladder (PREFER study). Int Urogynecol J. 2018;29(2):273–83. https://doi.org/10.1007/s00192-017-3377-5.CrossRefPubMed

Elmer-Lyon CG, Streit JA, Takacs EB, Ten Eyck PP, Bradley CS. Urinary tract infection and drug-resistant urinary tract infection after intradetrusor onabotulinumtoxinA injection versus sacral neuromodulation. Int Urogynecol J. 2019. https://doi.org/10.1007/s00192-019-04007-7.

Iyer S, Laus K, Rugino A, Botros C, Lozo S, Botros SM, et al. Subjective and objective responses to PTNS and predictors for success: a retrospective cohort study of percutaneous tibial nerve stimulation for overactive bladder. Int Urogynecol J. 2019;30(8):1253–9. https://doi.org/10.1007/s00192-018-3822-0.CrossRefPubMed

FDA Approves Mirabegron, Solifenacin Combo for OAB. http://fdadaily.com/2018/05/09/fda-approves-mirabegron-solifenacin-combo-for-oab/. 2018. Accessed 7/15/2019.

10.

Abrams P, Kelleher C, Staskin D, Kay R, Martan A, Mincik I, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: exploratory responder analyses of efficacy and evaluation of patient-reported outcomes from a randomized, double-blind, factorial, dose-ranging, phase II study (SYMPHONY). World J Urol. 2017;35(5):827–38. https://doi.org/10.1007/s00345-016-1908-1.CrossRefPubMed

11.

Drake MJ, Chapple C, Esen AA, Athanasiou S, Cambronero J, Mitcheson D, et al. Efficacy and safety of mirabegron add-on therapy to solifenacin in incontinent overactive bladder patients with an inadequate response to initial 4-week solifenacin monotherapy: a randomised double-blind multicentre phase 3B study (BESIDE). Eur Urol. 2016;70(1):136–45. https://doi.org/10.1016/j.eururo.2016.02.030.CrossRefPubMed

12.

Herschorn S, Chapple CR, Abrams P, Arlandis S, Mitcheson D, Lee KS, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU Int. 2017;120(4):562–75. https://doi.org/10.1111/bju.13882.CrossRefPubMed

Titel: Combination pharmacotherapy for the treatment of the overactive bladder syndrome: a new solution for an old problem?
verfasst von: Ahmed El-Zawahry
Diaa E. E. Rizk
Publikationsdatum: 12.11.2019
Verlag: Springer International Publishing
Erschienen in: International Urogynecology Journal / Ausgabe 5/2020
Print ISSN: 0937-3462
Elektronische ISSN: 1433-3023
DOI: https://doi.org/10.1007/s00192-019-04121-6

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Combination pharmacotherapy for the treatment of the overactive bladder syndrome: a new solution for an old problem?

Excerpt

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Update Gynäkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2020

Distal colpocleisis for actinic vesico-vaginal-rectal fistulas, a simple resolution for a complex problem

Physiotherapy assessment for female urinary incontinence

Better together: multidisciplinary approach improves adherence to pelvic floor physical therapy

Urinary metabolomics predict the severity of overactive bladder syndrome in an aging female population

Pelvic examination: an iatrogenic cause of microscopic hematuria in women?

Pelvic floor dysfunctions in female cheerleaders: a cross-sectional study

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

ICI-Therapie in der Schwangerschaft wird gut toleriert

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

Update Gynäkologie